Join
Live feed
·
PRReleasevia Quantisnow
Karuna Therapeutics Inc. logo

Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia

ByQuantisnow·Wall Street's wire, on your screen.
KRTX· Karuna Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KRTX (Karuna Therapeutics Inc.) and more on Quantisnow.